NANJING, China, Dec. 7, 2025 /PRNewswire/ -- From December 6 to 9, 2025, the 67th Annual Meeting of the American Society of Hematology ("ASH") was held in Orlando, Florida, USA. Nanjing Leads Biolabs ...

Jaypirca showed higher ORR than Imbruvica in both treatment-naive and relapsed/refractory CLL/SLL patients, with 87% vs. 78.5% overall. Progression-free survival trends favored Jaypirca, particularly ...

Black Diamond Therapeutics, Inc. (NASDAQ: BDTX) released topline data on Wednesday from its Phase 2 trial of silevertinib in frontline (1L) non-small cell lung cancer (NSCLC) patients with ...

BENGALURU, Nov 14 (Reuters) - India put new privacy rules into force on Friday that will make Meta, Google, OpenAI and other companies minimize collection of personal data and give people more control ...

SOUTH SAN FRANCISCO, Calif., Oct. 20, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a leading precision medicine oncology company, announced the first reported median overall survival ...

Hutchmed's fruquintinib and Eli Lilly & Innovent Biologics' Tyvyt (sintilimab) significantly improved PFS during a Phase III trial in second-line renal cell carcinoma (RSS). Image credit: Kateryna Kon ...

The Department of Labor is initiating an investigation into how the Bureau of Labor Statistics collects and reports “closely watched economic data,” according to a letter the department’s Assistant ...

HOUSTON -- Already indicated for relapsed/refractory follicular lymphoma, the bispecific antibody mosunetuzumab (Lunsumio) showed early promise for improving outcomes in two key lymphoma subtypes, ...

The AWS Certified Data Engineer Associate exam validates your ability to design, build, and maintain data processing systems that support analytics and business intelligence across AWS services. It ...

Immuneering Corporation IMRX announced that it has entered into a clinical supply agreement with pharma giant Eli Lilly LLY for the latter’s second-generation KRAS G12C inhibitor, olomorasib ...

Pirtobrutinib had a nominally superior overall response rate compared to ibrutinib in certain patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The non-covalent ...

As advancements in cancer treatment continue to evolve, the pursuit of more effective therapies for metastatic colorectal cancer remains a critical focus in the pharmaceutical industry. Cardiff ...